Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Journal Information
Full Title: Rev Soc Bras Med Trop
Abbreviation: Rev Soc Bras Med Trop
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Tropical Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of Interest: None of the authors have any conflicts of interest or financial ties to disclose."
"Financial Support: This study was fully funded by the Brazilian governmental agency, the National Council for Scientific and Technological Development (CNPq Brazil), in partnership with the Ministry of Science, Technology, and Innovation (Rede Vírus MCTI), Process no. 402422/2020-1, and 309098/2020-3."
"The STRUCK trial was conducted in accordance with ethical principles of human experimentation and with the Declaration of Helsinki revised in 2000. All sites received approval from the Institutional Review Board (CAAE 37880620.0.1001.5440), and the study was registered at ClinicalTrials.gov (NCT04724629). All patients or their legal representatives signed an informed consent form before the study procedure."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025